Breaking clinical trial news from ESMO 2023
Drug Discovery World
NOVEMBER 1, 2023
Durvalumab and olaparib, AstraZeneca A primary analysis of the DUO-E Phase III trial investigating durvalumab and olaparib in advanced or recurrent endometrial cancer showed an improvement in PFS compared to chemotherapy, reducing the risk-of disease progression or death by 45%. Median PFS was 13.8 months compared to 4.9 compared to 22.9%.
Let's personalize your content